Peginterferon α-2b Enhances Hepatitis B Surface Antigen Loss in Nucleos(t)ide Analogue-suppressed Low Hepatitis B Surface Antigen Chronic Hepatitis B Patients: Everest Study in China
Key Points
Hepatitis B surface antigen loss increased with peginterferon treatment, indicating a significant outcome.
Patients experienced enhanced antigen loss, with results compelling in nucleos(t)ide analogue-suppressed cases.
Assessment using clinical data involved chronic hepatitis B patients already on nucleos(t)ide analogue therapy.
These findings highlight the potential of peginterferon to improve management of chronic hepatitis B, although real-world effects need further evaluation.
Like
Bookmark
Share
Like
Bookmark
Share
Peginterferon α-2b Enhances Hepatitis B Surface Antigen Loss in Nucleos(t)ide Analogue-suppressed Low Hepatitis B Surface Antigen Chronic Hepatitis B Patients: Everest Study in China | Synapse